Eli Lilly and Company (TSX:LLY)

Market Cap	1.24T
Revenue (ttm)	82.77B +45.4%
Net Income	25.65B +120.0%
EPS	28.47 +121.0%
Shares Out	n/a
PE Ratio	48.53
Forward PE	32.23
Dividend	0.22 (0.59%)
Ex-Dividend Date	Nov 14, 2025

Volume	39,794
Average Volume	19,456
Open	37.56
Previous Close	37.60
Day's Range	36.42 - 37.56
52-Week Range	22.85 - 41.00
Beta	n/a
RSI	42.43
Earnings Date	Feb 4, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD